CELEBREX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Celebrex, and when can generic versions of Celebrex launch?
Celebrex is a drug marketed by Upjohn and is included in one NDA.
The generic ingredient in CELEBREX is celecoxib. There are twenty-six drug master file entries for this compound. Sixty-two suppliers are listed for this compound. Additional details are available on the celecoxib profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Celebrex
A generic version of CELEBREX was approved as celecoxib by TEVA on May 30th, 2014.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CELEBREX?
- What are the global sales for CELEBREX?
- What is Average Wholesale Price for CELEBREX?
Summary for CELEBREX
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 7 |
Raw Ingredient (Bulk) Api Vendors: | 175 |
Clinical Trials: | 240 |
Patent Applications: | 4,537 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for CELEBREX |
Drug Sales Revenues: | Drug sales revenues for CELEBREX |
What excipients (inactive ingredients) are in CELEBREX? | CELEBREX excipients list |
DailyMed Link: | CELEBREX at DailyMed |
![CELEBREX drug patent expirations Drug patent expirations by year for CELEBREX](/p/graph/s/t/CELEBREX-patent-expirations.png)
![Drug Prices for CELEBREX](/p/graph/drug-price/CELEBREX.png)
![Drug Sales Revenue Trends for CELEBREX](/p/graph/drug-sales-revenues/CELEBREX.png)
Recent Clinical Trials for CELEBREX
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Miami | Phase 3 |
Translational Genomics Research Institute | Phase 1 |
HonorHealth Research Institute | Phase 1 |
Pharmacology for CELEBREX
Drug Class | Nonsteroidal Anti-inflammatory Drug |
Mechanism of Action | Cyclooxygenase Inhibitors |
US Patents and Regulatory Information for CELEBREX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Upjohn | CELEBREX | celecoxib | CAPSULE;ORAL | 020998-004 | Dec 15, 2006 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Upjohn | CELEBREX | celecoxib | CAPSULE;ORAL | 020998-003 | Aug 29, 2002 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Upjohn | CELEBREX | celecoxib | CAPSULE;ORAL | 020998-001 | Dec 31, 1998 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Upjohn | CELEBREX | celecoxib | CAPSULE;ORAL | 020998-002 | Dec 31, 1998 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CELEBREX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Upjohn | CELEBREX | celecoxib | CAPSULE;ORAL | 020998-002 | Dec 31, 1998 | ⤷ Sign Up | ⤷ Sign Up |
Upjohn | CELEBREX | celecoxib | CAPSULE;ORAL | 020998-001 | Dec 31, 1998 | ⤷ Sign Up | ⤷ Sign Up |
Upjohn | CELEBREX | celecoxib | CAPSULE;ORAL | 020998-001 | Dec 31, 1998 | ⤷ Sign Up | ⤷ Sign Up |
Upjohn | CELEBREX | celecoxib | CAPSULE;ORAL | 020998-003 | Aug 29, 2002 | ⤷ Sign Up | ⤷ Sign Up |
Upjohn | CELEBREX | celecoxib | CAPSULE;ORAL | 020998-003 | Aug 29, 2002 | ⤷ Sign Up | ⤷ Sign Up |
Upjohn | CELEBREX | celecoxib | CAPSULE;ORAL | 020998-004 | Dec 15, 2006 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for CELEBREX
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Pfizer Limited | Onsenal | celecoxib | EMEA/H/C/000466 Onsenal is indicated for the reduction of the number of adenomatous intestinal polyps in familial adenomatous polyposis (FAP), as an adjunct to surgery and further endoscopic surveillance (see section 4.4).The effect of Onsenal-induced reduction of polyp burden on the risk of intestinal cancer has not been demonstrated (see sections 4.4 and 5.1) |
Withdrawn | no | no | no | 2003-10-17 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for CELEBREX
See the table below for patents covering CELEBREX around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Spain | 2172959 | ⤷ Sign Up | |
Austria | 212985 | ⤷ Sign Up | |
Germany | 69429836 | ⤷ Sign Up | |
Hungary | 223824 | Gyulladáscsökkentő hatású szubsztituált pirazolil-benzol-szulfonamid-származékok, ilyen vegyületeket tartalmazó gyógyszerkészítmények és eljárás azok előállítására (SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR PRODUCING THEM) | ⤷ Sign Up |
European Patent Office | 0924201 | Pyrazolyl-benzènesulfonamides tricycliques substitués utilisés comme inhibiteurs de la cyclooxygénase-2 (Tricyclic-substituted pyrazolyl benzenesulfonamides and their use as cyclooxygenase II inhibitors) | ⤷ Sign Up |
South Korea | 100261669 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CELEBREX
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0731795 | 91538 | Luxembourg | ⤷ Sign Up | 91538, EXPIRES: 20191114 |
0731795 | C300380 | Netherlands | ⤷ Sign Up | PRODUCT NAME: MAVACOXIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/2/08/084/001-005 20080909 |
0731795 | SPC/GB09/010 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: MAVACOXIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/2/08/084/001 20080909; UK EU/2/08/084/002 20080909; UK EU/2/08/084/003 20080909; UK EU/2/08/084/004 20080909; UK EU/2/08/084/005 20080909 |
0731795 | 09C0007 | France | ⤷ Sign Up | PRODUCT NAME: MAVACOXIB; REGISTRATION NO/DATE: EU/2/08/084/001 20080909 |
0731795 | 4/2009 | Austria | ⤷ Sign Up | PRODUCT NAME: MAVACOXIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES; REGISTRATION NO/DATE: EU/2/08/084/001-005 20080909 |
0731795 | CA 2009 00005 | Denmark | ⤷ Sign Up | PRODUCT NAME: MAVACOXIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |